Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo Q L
Japanese Red Cross Central Blood Center, Tokyo.
Cancer. 1991 Jan 15;67(2):429-33. doi: 10.1002/1097-0142(19910115)67:2<429::aid-cncr2820670218>3.0.co;2-#.
In Japan, hepatocellular carcinoma (HCC) is one of the most prevalent cancers, with a reported fatality rate showing a consistent and significant increase in the last decade. At most, only 25% of HCC cases are positive for the hepatitis B surface antigen (HBsAg). To investigate a potential role for hepatitis C virus (HCV) in the development of HCC, sera from 105 HBsAg-negative HCC patients were collected from five districts of Japan and assayed for antibody to HCV antigen (HCVAb). A large number of these patients (76.2%) were found to be positive for the HCVAb in comparison with the reported prevalence in sera from blood donors (1.1%). A history of blood transfusion was found in 39.6% of the cases positive for HCVAb, which was significantly different to the lower rate (4.7%) observed in HCC patients who were both positive for HBsAg and negative for HCVAb (P less than 0.001).
在日本，肝细胞癌（HCC）是最常见的癌症之一，据报道其死亡率在过去十年中持续显著上升。最多只有25%的HCC病例乙肝表面抗原（HBsAg）呈阳性。为了研究丙型肝炎病毒（HCV）在HCC发生发展中的潜在作用，从日本五个地区收集了105例HBsAg阴性的HCC患者的血清，并检测了抗HCV抗原抗体（HCVAb）。与献血者血清中报告的患病率（1.1%）相比，发现这些患者中有大量（76.2%）的HCVAb呈阳性。在HCVAb阳性的病例中，39.6%有输血史，这与HBsAg阳性且HCVAb阴性的HCC患者中观察到的较低比例（4.7%）有显著差异（P小于0.001）。
